

---

## Overview

### Useful For

Monitoring serum concentration of desipramine during therapy

Evaluating potential desipramine toxicity

The test may also be useful to evaluate patient compliance

### Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum Red

### Specimen Required

**Collection Container/Tube:** Red top (Serum gel/SST are **not acceptable**)

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

### Collection Instructions:

1. Collect specimen immediately before next scheduled dose (minimum 12 hours after last dose).
2. Centrifuge and aliquot serum into plastic vial. **Serum must be separated from cells within 2 hours of collection.**

### Forms

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

---

**Reject Due To**

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	Reject

**Specimen Minimum Volume**

0.25 mL

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum Red	Refrigerated (preferred)	28 days	
	Frozen	28 days	
	Ambient	7 days	

**Clinical & Interpretive****Clinical Information**

Desipramine is a tricyclic antidepressant; it also is a metabolite of imipramine. These drugs have also been employed in the treatment of enuresis (involuntary urination) in childhood and severe obsessive-compulsive neurosis. Desipramine is the antidepressant of choice in patients where maximal stimulation is indicated.

The therapeutic concentration of desipramine is 100 to 300 ng/mL. About 1 to 3 weeks of treatment are required before therapeutic effectiveness becomes apparent.

The most frequent side effects are those attributable to anticholinergic effects: dry mouth, constipation, dizziness, tachycardia, palpitations, blurred vision, and urinary retention. These occur at blood concentrations in excess of 400 ng/mL, although they may occur at therapeutic concentrations in the early stage of therapy. Cardiac toxicity (first-degree heart block) is usually associated with blood concentrations in excess of 400 ng/mL.

**Reference Values**

Therapeutic concentration: 100-300 ng/mL

**Note:** Therapeutic ranges are for specimens collected at trough (ie, immediately before next scheduled dose).

Levels may be elevated in non-trough specimens.

---

**Interpretation**

Most individuals display optimal response to desipramine with serum levels of 100 to 300 ng/mL. Some individuals may respond well outside of this range or may display toxicity within the therapeutic range; thus, interpretation should include clinical evaluation. Risk of toxicity is increased with levels above 400 ng/mL.

**Cautions**

This test cannot be performed on whole blood. Serum must be separated from cells within 2 hours of collection; if serum is not removed within this time, tricyclic antidepressant levels may be falsely elevated due to drug release from red blood cells.

Specimens that are obtained from gel tubes are not acceptable, as the drug can absorb on the gel and lead to falsely decreased concentrations.

**Clinical Reference**

[1. Wille SM, Cooreman SG, Neels HM, Lambert WE: Relevant issues in the monitoring and toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45\(1\):25-89](#)

2. Thanacoody HK, Thomas SH: Antidepressant poisoning. Clin Med. 2003;3(2):114-118

3. Hiemke C, Baumann P, Bergemann N, et al: AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011;44(6):195-235

4. Burtis CA, Ashwood ER, Bruns ED, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. Elsevier; 2012

**Performance****Method Description**

The tricyclic antidepressants are extracted from serum using a solvent crash to precipitate proteins. The supernatant is removed and analysis is by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (Unpublished Mayo method)

**PDF Report**

No

**Specimen Retention Time**

14 days

---

**Performing Laboratory Location**

Rochester

**Fees & Codes****Test Classification**

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

80335

G0480 (if appropriate)

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
DESPR	Desipramine, S	3531-1

Result ID	Reporting Name	LOINC®
37123	Desipramine, S	3531-1